| Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial A Osinusi, EG Meissner, YJ Lee, D Bon, L Heytens, A Nelson, M Sneller, ... Jama 310 (8), 804-811, 2013 | 397 | 2013 |
| Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis DHS Tan, MW Hull, D Yoong, C Tremblay, P O’byrne, R Thomas, J Kille, ... Cmaj 189 (47), E1448-E1458, 2017 | 210 | 2017 |
| Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study A Kohli, A Osinusi, Z Sims, A Nelson, EG Meissner, LL Barrett, D Bon, ... The Lancet 385 (9973), 1107-1113, 2015 | 181 | 2015 |
| Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study AD Marshall, S Saeed, L Barrett, CL Cooper, C Treloar, J Bruneau, ... Canadian Medical Association Open Access Journal 4 (4), E605-E614, 2016 | 95 | 2016 |
| Immune resilience in HIV-infected individuals seronegative for cytomegalovirus L Barrett, SN Stapleton, NJ Fudge, MD Grant Aids 28 (14), 2045-2049, 2014 | 61 | 2014 |
| Cytomegalovirus, aging, and HIV: a perfect storm L Barrett, KR Fowke, MD Grant AIDS Rev 14 (3), 159-67, 2012 | 60 | 2012 |
| Biomedical HIV Prevention Working Group of the CIHR Canadian HIV Trials Network. Canadian guideline on HIV pre-exposure prophylaxis and nonoccupational postexposure prophylaxis DHS Tan, MW Hull, D Yoong, C Tremblay, P O’Byrne, R Thomas, J Kille, ... CMAJ 189 (47), E1448-E1458, 2017 | 39 | 2017 |
| CIHR Canadian HIV trials network coinfection and concurrent diseases core research group: 2016 updated Canadian HIV/hepatitis C adult guidelines for management and treatment M Hull, S Shafran, A Wong, A Tseng, P Giguère, L Barrett, S Haider, ... Canadian Journal of Infectious Diseases and Medical Microbiology 2016 (1 …, 2016 | 37 | 2016 |
| Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals L Barrett, M Gallant, C Howley, MI Bowmer, G Hirsch, K Peltekian, M Grant BMC immunology 9, 1-16, 2008 | 35 | 2008 |
| Investigating the sensitivity of nasal or throat swabs: combination of both swabs increases the sensitivity of SARS-CoV-2 rapid antigen tests BL Goodall, JJ LeBlanc, TF Hatchette, L Barrett, G Patriquin Microbiology Spectrum 10 (4), e00217-22, 2022 | 34 | 2022 |
| Real‐world impact of direct acting antiviral therapy on health‐related quality of life in HIV/Hepatitis C co‐infected individuals S Saeed, EEM Moodie, E Strumpf, J Gill, A Wong, C Cooper, S Walmsley, ... Journal of viral hepatitis 25 (12), 1507-1514, 2018 | 30 | 2018 |
| Host Gene Expression Changes Correlating With Anti–HIV-1 Effects in Human Subjects After Treatment With Peginterferon Alfa-2a JJ Hubbard, T Greenwell-Wild, L Barrett, J Yang, RA Lempicki, SM Wahl, ... Journal of Infectious Diseases 205 (9), 1443-1447, 2012 | 28 | 2012 |
| Epidemiologic and clinical features of chronic hepatitis B virus infection in 8 Canadian provinces: a descriptive study by the Canadian HBV Network CS Coffin, A Ramji, CL Cooper, D Miles, KE Doucette, P Wong, E Tam, ... Canadian Medical Association Open Access Journal 7 (4), E610-E617, 2019 | 27 | 2019 |
| Canadian Association of Gastroenterology clinical practice guideline for immunizations in patients with inflammatory bowel disease (IBD)—part 1: live vaccines EI Benchimol, F Tse, MW Carroll, JC deBruyn, SA McNeil, A Pham-Huy, ... Journal of the Canadian Association of Gastroenterology 4 (4), e59-e71, 2021 | 25 | 2021 |
| CMV retinopathy in the antiretroviral therapy era: prevention, diagnosis, and management L Barrett, S Walmsley Current infectious disease reports 14, 435-444, 2012 | 23 | 2012 |
| High Efficacy Of GS-7977 In Combination With Low or Full dose Ribavirin for 24 weeks In Difficult To Treat HCV Infected Genotype 1 Patients: Interim Analysis From The SPARE … A Osinusi, L Heytens, YJ Lee, D Bon, B Shivakumar, A Nelson, ... Hepatology 56 (6), 1518A, 2012 | 22 | 2012 |
| Transmission characteristics of SARS-CoV-2 variants of concern Rapid Scoping Review J Curran, J Dol, L Boulos, M Somerville, H McCulloch, M MacDonald, ... MedRxiv, 2021.04. 23.21255515, 2021 | 21 | 2021 |
| Canadian association of gastroenterology clinical practice guideline for immunizations in patients with Inflammatory Bowel Disease (IBD)—part 2: inactivated vaccines JL Jones, F Tse, MW Carroll, JC deBruyn, SA McNeil, A Pham-Huy, ... Journal of the Canadian Association of Gastroenterology 4 (4), e72-e91, 2021 | 20 | 2021 |
| Responses to pandemic ASO3-adjuvanted A/California/07/09 H1N1 influenza vaccine in human immunodeficiency virus-infected individuals D Kelly, K Burt, B Missaghi, L Barrett, Y Keynan, K Fowke, M Grant BMC immunology 13, 1-9, 2012 | 19 | 2012 |
| Circulating CD14−CD36+ peripheral blood mononuclear cells constitutively produce interleukin-10 L Barrett, C Dai, J Gamberg, M Gallant, M Grant Journal of Leucocyte Biology 82 (1), 152-160, 2007 | 19 | 2007 |
